Targeting HER2 in BC has shown effectiveness in clinical trial, which offers a reliable treatment option (Duffy et al., 2015; Krishnamurti & Silverman, 2014; Moasser & Krop, 2015). This evidence concerns the gene ERBB2 and breast cancer.